


NEW PROSTAGLANDINE PREPARATION FOR OBSTETRICS AND GYNECOLOGY

Ivanova N.A., Sapozhnikova T.A., Zarudii F.S., Miftakhov M.S.

Ufa Institute of Chemistry UFRC RAS, 450054, Russia, Ufa, pr.Oktyabrya, 71;
e-mail: bioreg@anrb.ru

In obstetrics and gynecology for the early termination of pregnancy (abortion), induction of labor (obstetric aid) and treatment of postpartum complications, the preparations based on steroid RU 486 and prostaglandin (PG) Misoprostol (combination "a") are successfully used. We propose a new, equally active Misoprostol for this purpose, the prostaglandin component in combination "b" - 11-deoxymisoprostol (DMP), which, unlike misoprostol, is synthetically easily available, less toxic and more stable during storage.



To date, preclinical studies of DMP have been completed (FTP "Pharma-2020" and State Contract No. 14.N08.12.0013, 2013-2015). A dosage form of DMP has been developed, which has high bioavailability (86%), stability and preservation of uterotonic and abortive properties over the entire shelf life (2 years). Optimal doses of medicines and mifepristone for combined medical abortion in rats in early pregnancy were detected. DMP was found to show a more pronounced luteolytic action in the abortive dose and having 2 times more therapeutic width, allows to increase the abortive effect of the mifepristone – DMM tandem by increasing the dose of PG. Laboratory and pilot industrial regulations have been developed for pharmaceutical substances and medicines.

The work was done on the topic №AAAA-A17-117011910032-4 of state assignment.